Literature DB >> 12107774

Antitumor effects induced by the combination of TNP-470 as an angiogenesis inhibitor and lentinan as a biological response modifier in a rabbit spontaneous liver metastasis model.

Bun Sano1, Yasuyuki Sugiyama, Katsuyuki Kunieda, Jun Sano, Shigetoyo Saji.   

Abstract

PURPOSE: An angiogenesis inhibitor, TNP-470 (TNP), has shown promising results in tumor dormancy therapy, and we have been studying its antitumor effects using a rabbit spontaneous liver metastasis model. However, because inhibition was observed only at the step of micrometastasis, we examined the effects of combining TNP in the same model with a nonspecific immunopotentiator, lentinan (LNT), as a biological response modifier.
METHODS: The model was established by the inoculation of VX-2 tumors into the colon, and colectomy was subsequently performed, including the primary tumor. Combination (TNP + LNT) effects were evaluated in terms of the number and volume of metastatic nodules, microvessel density (MVD), expression of proliferating cell nuclear antigen (PCNA), and apoptosis, using immunohistochemical staining with anti-CD31, anti-PCNA monoclonal antibody, and the TUNEL (in situ nick end-labeling) method, respectively.
RESULTS: Angiogenesis was significantly inhibited in the TNP + LNT group, and the apoptotic index was also significantly higher than in the TNP or LNT groups. The positive expression of PCNA in the VX2 cells was reduced in the LNT alone and TNP + LNT groups, but not in the TNP alone group.
CONCLUSION: These findings indicate that TNP-470 and lentinan could prove useful for preventing the development of metachronous liver metastases from colorectal cancers after curative resection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107774     DOI: 10.1007/s005950200085

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  8 in total

1.  Establishment and identification of a rabbit model of peritoneal carcinomatosis from gastric cancer.

Authors:  Lie-Jun Mei; Xiao-Jun Yang; Li Tang; Alaa Hammed Al-Shammaa Hassan; Yutaka Yonemura; Yan Li
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

2.  Expression of PCNA and CD44mRNA in colorectal cancer with venous invasion and its relationship to liver metastasis.

Authors:  Shu-Qiang Yue; Yan-Ling Yang; Ke-Feng Dou; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

3.  Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization.

Authors:  Zhen Li; Dao-Yu Hu; Qian Chu; Jian-Hong Wu; Chun Gao; Yu-Qing Zhang; Yan-Rong Huang
Journal:  World J Gastroenterol       Date:  2004-07-01       Impact factor: 5.742

4.  Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.

Authors:  Vinay Bhaskar; Melvin Fox; Danna Breinberg; Melanie H-L Wong; Pauline E Wales; Susan Rhodes; Robert B DuBridge; Vanitha Ramakrishnan
Journal:  Invest New Drugs       Date:  2007-09-01       Impact factor: 3.850

5.  Interferon-beta inhibits liver metastases from murine colon 26 carcinoma and its highly metastatic variant.

Authors:  Shigechika Kohashi; Yuji Sato; Tsuyoshi Fukushima; Hiroki Shomura; Takahiro Oshima; Sun Bairun; Masao Kondo; Yoshie Une; Jun Nishihira; Satoru Todo
Journal:  Surg Today       Date:  2007-05-28       Impact factor: 2.549

6.  Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer.

Authors:  Qin Jiang; Shuai Pang; Yifang Xia; Hongmei Sun; Yingying Yu
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-09       Impact factor: 2.650

7.  Dynamical observation on biological progression of VX2 liver tumors to identify the optimal time for intervention in animal models.

Authors:  Zhenguang Wang; Guangjie Yang; Pei Nie; Junhua Fu; Xufu Wang; Dan Liu
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner.

Authors:  Shengming Deng; Guoxi Zhang; Jiajie Kuai; Peng Fan; Xuexiang Wang; Pei Zhou; Dan Yang; Xichen Zheng; Xiaomei Liu; Qunli Wu; Yuhui Huang
Journal:  J Exp Clin Cancer Res       Date:  2018-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.